Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT04319783
Title Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMA (DECREASE)
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Trans Tasman Radiation Oncology Group
Indications

prostate adenocarcinoma

Therapies

Darolutamide

Age Groups: senior | adult
Covered Countries


No variant requirements are available.